The use of botulinum toxin type A in the management of adult-onset focal spasticity: A survey of Australian allied health professionals

Australian Occupational Therapy Journal

Volumn 59, Issue 4, 2012, Pages 257-264

  Williams, Gavin ^a   Olver, John ^a   de Graaff, Stephen ^a   Singer, Barbara J ^b  

^a Epworth Monash Rehabilitation Medicine Unit   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Botulinum toxins; Muscle hypertonia; Muscle spasticity; Physical therapy modalities; Rehabilitation

Indexed keywords

BOTULINUM TOXIN A; NEUROTOXIN;

ADULT; ARTICLE; AUSTRALIA; HEALTH CARE SURVEY; HEALTH PERSONNEL ATTITUDE; HUMAN; INTERNET; METHODOLOGY; OCCUPATIONAL THERAPY; PHYSIOTHERAPY; PRACTICE GUIDELINE; QUESTIONNAIRE; SPASTICITY; STANDARD; STATISTICS;

ADULT; ATTITUDE OF HEALTH PERSONNEL; AUSTRALIA; BOTULINUM TOXINS, TYPE A; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HUMANS; INTERNET; MUSCLE SPASTICITY; NEUROTOXINS; OCCUPATIONAL THERAPY; PHYSICAL THERAPY MODALITIES; PRACTICE GUIDELINES AS TOPIC; QUESTIONNAIRES;

EID: 84865626332     PISSN: 00450766     EISSN: 14401630     Source Type: Journal    
DOI: 10.1111/j.1440-1630.2012.01027.x     Document Type: Article

References (23)

1. Bohannon, R. W. & Smith, M. B. (1987). Interrater reliability of the modified Ashworth scale of muscle spasticity. Physical Therapy, 67, 206-207.
2. Brashear, A. & Lambeth, K. (2009). Spasticity. Current Treatment Options in Neurology, 11 (3), 153-161.
3. Department of Human Services, Australian Government(2012). Botulinum Toxin. Retrieved 23 March, 2012, from http://www.medicareaustralia.gov.au/provider/pbs/drugs1/botulinum.jsp#N10026.
4. Elia, A. E., Filippini, G., Calandrella, D. & Albanese, A. (2009). Botulinum neurotoxins for post-stroke spasticity in adults: a systematic review. Movement Disorders, 24 (6), 801-812.
5. Esquenazi, A., Mayer, N. H., Elia, A. E. & Albanese, A. (2009). Botulinum toxin for the management of adult patients with upper motor neuron syndrome. Toxicon, 54 (5), 634-638.
6. Esquenazi, A., Novak, I., Sheean, G., Singer, B. J. & Ward, A. B. (2010). International consensus statement for the use of botulinum toxin treatment in adults and children with neurological impairments-introduction. European Journal of Neurology, 17 (Suppl 2), 1-8.
7. Gracies, J. M., Marosszeky, J. E., Renton, R., Sandanam, J., Gandevia, S. C. & Burke, D. (2000). Short-term effects of dynamic lycra splints on upper limb in hemiplegic patients. Archives of Physical Medicine and Rehabilitation, 81 (12), 1547-1555.
8. Granger, C. V., Hamilton, B. B. & Sherwin, F. S. (1983). Guide for the use of the uniform data set for medical rehabilitation. Buffalo General Hospital, New York: Uniform Data System for Medical rehabilitation Project Office.
9. van Kuijk, A. A., Hendricks, H. T., Pasman, J. W., Kremer, B. H. & Geurts, A. C. (2007). Are clinical characteristics associated with upper-extremity hypertonia in severe ischaemic supratentorial stroke? Journal of Rehabilitation Medicine, 39 (1), 33-37.
10. Lapeyre, E., Kuks, J. B. M. & Meijler, W. J. (2010). Spasticity: revisiting the role and the individual value of several pharmacological treatments. NeuroRehabilitation, 27 (2), 193-200.
11. Lundstrom, E., Smits, A., Terent, A. & Borg, J. (2010). Time-course and determinants of spasticity during the first six months following first-ever stroke. Journal of Rehabilitation Medicine, 42 (4), 296-301.
12. Olver, J., Esquenazi, A., Fung, V. S. C., Singer, B. J., Ward, A. B. & Cerebral Palsy Institute (2010). Botulinum toxin assessment, intervention and aftercare for lower limb disorders of movement and muscle tone in adults: international consensus statement. European Journal of Neurology, 17 (Suppl 2), 57-73.
13. Rizzo, M. A., Hadjimichael, O. C., Preiningerova, J. & Vollmer, T. L. (2004). Prevalence and treatment of spasticity reported by multiple sclerosis patients. Multiple Sclerosis, 10 (5), 589-595.
14. Royal College of Physicians, British Society of Rehabilitation Medicine, & Chartered Society of Physiotherapy. (2009). Spasticity in adults: management using botulinum toxin. National guidelines. London: Royal College of Physicians.
15. Sheean, G., Lannin, N. A., Turner-Stokes, L., Rawicki, B., Snow, B. J. & Cerebral Palsy, I. (2010). Botulinum toxin assessment, intervention and after-care for upper limb hypertonicity in adults: international consensus statement. European Journal of Neurology, 17 (Suppl 2), 74-93.
16. Simpson, D. M., Gracies, J. M., Graham, H. K., Miyasaki, J. M., Naumann, M., Russman, B. et al. (2008). Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology, 70 (19), 1691-1698.
17. Smania, N., Picelli, A., Munari, D., Geroin, C., Ianes, P., Waldner, A. et al. (2010). Rehabilitation procedures in the management of spasticity. European Journal of Physical Rehabilitation and Medicine, 46 (3), 423-438.
18. Tardieu, G., Shentoub, S. & Delarue, R. (1954). A la recherche d'une technique de mesure de la spasticite. Revue Neurologique, 91, 143-144.
19. Tiffin, J. & Asher, E. J. (1948). The Purdue Pegboard: Norms and studies of reliability and validity. Journal of Applied Psychology, 32, 234-247.
20. Turner-Stokes, L., Williams, H. & Johnson, J. (2009). Goal attainment scaling: does it provide added value as a person-centred measure for evaluation of outcome in neurorehabilitation following acquired brain injury? Journal of Rehabilitation Medicine, 41 (7), 528-535.
21. Urban, P. P., Wolf, T., Uebele, M., Marx, J. J., Vogt, T., Stoeter, P. et al. (2010). Occurence and clinical predictors of spasticity after ischemic stroke. Stroke, 41 (9), 2016-2020.
22. Watkins, C. L., Leathley, M. J., Gregson, J. M., Moore, A. P., Smith, T. L. & Sharma, A. K. (2002). Prevalence of spasticity post stroke. Clinical Rehabilitation, 16 (5), 515-522.
23. Wissel, J., Ward, A. B., Erztgaard, P., Bensmail, D., Hecht, M. J., Lejeune, T. M. et al. (2009). European consensus table on the use of botulinum toxin type A in adult spasticity. Journal of Rehabilitation Medicine, 41 (1), 13-25.